On the stock market since 2020, it operates in the world of health and science. It has 100 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Revenue is spread across several lines; no single product carries the company.
Average growth of 83% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 84% a year on average.
Sales run at $29.6M a year. A small number, but proof the product has real buyers.
A loss of $24.0M against $29.6M in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
The stock trades 13% above the average analyst price target.
On our five-subject report card, NBTX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NBTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.